Inhibiting an RBM39/MLL1 Epigenomic Regulatory Complex with Dominant-Negative Peptides Disrupts Cancer Cell Transcription and Proliferation

Scientists established RBM39/MLL1 as a major contributor to the abnormal epigenetic landscape in breast cancer and laid the foundation for peptide-mediated cancer-specific therapy based on disruption of RBM39 epigenomic functions.